tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Jul 26;10(7)
fad358.
doi: 10.1093/ofid/ofad358. eCollection 2023 Jul. Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis
Marta Colaneri[SUP] 1 2 [/SUP], Emanuele Maria Giusti[SUP] 3 [/SUP], Camilla Genovese[SUP] 1 4 [/SUP], Lucia Galli[SUP] 1 4 [/SUP], Andrea Lombardi[SUP] 4 5 [/SUP], Andrea Gori[SUP] 1 2 [/SUP]
Affiliations
Mortality of candidemia in coronavirus disease 2019 (COVID-19) patients has not been deeply studied despite evidence suggesting an increased occurrence. We performed a systematic review and meta-analysis to summarize the available evidence about these patients' mortality and length of stay. Data about the in-hospital, all-cause and 30-day mortality, and length of stay were pooled. Subgroup analyses were performed to assess sources of heterogeneity. Twenty-six articles out of the 1915 records retrieved during the search were included in this review. The pooled in-hospital mortality was 62.62% (95% CI, 54.77% to 69.86%), while the mortality in intensive care unit (ICU) was 66.77% (95% CI, 57.70% to 74.75%). The pooled median in-hospital length of stay was 30.41 (95% CI, 12.28 to 48.55) days, while the pooled median length of stay in the ICU was 28.28 (95% CI, 20.84 to 35.73) days. The subgroup analyses did not identify the sources of heterogeneity in any of the analyses. Our results showed high mortality in patients with candidemia and COVID-19, suggesting the need to consider screening measures to prevent this life-threatening condition.
Keywords: COVID-19; candidemia; meta-analysis; mortality; systematic review.
. 2023 Jul 26;10(7)
fad358.doi: 10.1093/ofid/ofad358. eCollection 2023 Jul. Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis
Marta Colaneri[SUP] 1 2 [/SUP], Emanuele Maria Giusti[SUP] 3 [/SUP], Camilla Genovese[SUP] 1 4 [/SUP], Lucia Galli[SUP] 1 4 [/SUP], Andrea Lombardi[SUP] 4 5 [/SUP], Andrea Gori[SUP] 1 2 [/SUP]
Affiliations
- PMID: 37520417
- PMCID: PMC10375424
- DOI: 10.1093/ofid/ofad358
Mortality of candidemia in coronavirus disease 2019 (COVID-19) patients has not been deeply studied despite evidence suggesting an increased occurrence. We performed a systematic review and meta-analysis to summarize the available evidence about these patients' mortality and length of stay. Data about the in-hospital, all-cause and 30-day mortality, and length of stay were pooled. Subgroup analyses were performed to assess sources of heterogeneity. Twenty-six articles out of the 1915 records retrieved during the search were included in this review. The pooled in-hospital mortality was 62.62% (95% CI, 54.77% to 69.86%), while the mortality in intensive care unit (ICU) was 66.77% (95% CI, 57.70% to 74.75%). The pooled median in-hospital length of stay was 30.41 (95% CI, 12.28 to 48.55) days, while the pooled median length of stay in the ICU was 28.28 (95% CI, 20.84 to 35.73) days. The subgroup analyses did not identify the sources of heterogeneity in any of the analyses. Our results showed high mortality in patients with candidemia and COVID-19, suggesting the need to consider screening measures to prevent this life-threatening condition.
Keywords: COVID-19; candidemia; meta-analysis; mortality; systematic review.